The Vial Preferred Site Network links specialised sites to sponsors for more efficient trials, that aid in bringing new treatments to the market. Credit: Daniel Sone / National Cancer Institute on Unsplash.

Vial has added NEXT Oncology, a worldwide Phase I cancer research clinics network, to its Preferred Site Network.

NEXT Oncology is headquartered in San Antonio, Texas, US, and has extended locations in the US and Spain.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Vial Preferred Site Network links specialised sites to sponsors for more efficient trials that aid in rapidly bringing new treatments into the market. The Vial CRO manages these trials.

The network investigators are selected through a thorough procedure, guaranteeing that each site is prepared for the smooth conduct of trials with technology-facilitated methods, from site startup to database lock. 

Investigators that become part of the Preferred Site Network of Vial attain exclusive access to trials, as well the chance to enhance their research business.

See Also:

Vial will utilise a new, Cloud-based software platform, proXimity, for automating the transmission of trial data from their electronic medical records (EMR) to the electronic data capture (EDC) systems of the sponsors. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Automating this method will expedite the performance of the trials, getting new treatments for cancer patients into the market faster.

NEXT Oncology co-founder Dr Anthony Tolcher said: “My mission and the mission of the company has always been to support and accelerate innovation in oncology in order to improve patient outcomes. 

“By investing in technologies that can accelerate innovation, we are able to contribute to this mission. 

“The approach and the technologies Vial is driving forward are exciting and could meaningfully contribute to making trials more efficient.”